Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls.
Martina CalusicRobert MarcecLea LuksaIvan JurkovicNatasa KovacSlobodan MihaljevicRobert LikićPublished in: British journal of clinical pharmacology (2021)
Fluvoxamine treatment in addition to the standard therapy in hospitalised ICU COVID-19 patients could have a positive impact on patient survival. Further studies on the effects of fluvoxamine in COVID-19 patients are urgently required.
Keyphrases
- sars cov
- intensive care unit
- end stage renal disease
- ejection fraction
- newly diagnosed
- clinical trial
- prognostic factors
- case report
- study protocol
- randomized controlled trial
- patient reported outcomes
- stem cells
- mesenchymal stem cells
- combination therapy
- phase ii
- smoking cessation
- community acquired pneumonia
- placebo controlled